Evaluation of Obex® in Overweight and Obesity

Overweight and Obesity Clinical Trial

Official title:

Efficacy and Safety of the Obex® Nutritional Supplement in Overweight and Obese Subjects: Phase III.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03541005
• Other study ID #: OBEX-CAT-2018
• Status: Completed
• Phase: Phase 3
• Start date: October 1, 2018
• Est. completion date: July 3, 2021

Study information

• Verified date: October 2021
• Source: Catalysis SL
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

• Obesity is an important and growing worldwide

• Obesity is highly related to the development of metabolic syndrome, diabetes, cardiovascular diseases and cancer

• Diverse adverse events have been reported with the use of antiobesity drugs.

• Several articles describe the beneficial effect of several specific components of the Obex® supplement on weight loss, in the reduction of waist circumference, suppression of appetite, decrease fasting glucose levels, improvement of insulin sensitivity and β cells function.

• Therefore, the administration of Obex in overweight and obese patients could be an excellent strategy to induce weight loss and ameliorate the metabolic disturbances related to obesity and overweight.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 160
• Est. completion date: July 3, 2021
• Est. primary completion date: September 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patients who fulfill the diagnosis criteria of overweight or obesity (BMI = 25.0 and less than 40).

• Age between 20 and 65 years old.

• Values of fasting glucose < 7.0 mmol / L and at two hours < 11.1 mmol / L during Glucose Tolerance Test (OGTT).

• Written informed consent of participation in the study.

Exclusion Criteria:

• Thyroid dysfunction (hypo or hyperthyroidism).

• Type 1 or type 2 diabetes.

• Prediabetes treated with oral agents.

• Alterations of lipids treated with drugs.

• Medicine consumption of or dietary supplements that influence the reduction of body weight.

• Consumption of steroids or prolonged use of them (last 3 months).

• Treatment with immunosuppressive drugs.

• Chronic diseases (of the hepatic, renal and cardiovascular systems, pancreatitis or some type of malignancy condition) or acute at the time of inclusion.

• Insulin resistance due to diseases such as acromegaly, endogenous hypercortisolism, polycystic ovarian syndrome or hyperprolactinemia.

• History of symptomatic hypoglycaemia.

• History of chronic debilitating diseases, anemia and collagen diseases.

• History or existence psychological illness with eating disorders or toxicity.

• History of alcoholism or drug dependence.

• Inability to comply with the instructions of the investigation.

• Severe infections at the time of inclusion.

• Women of childbearing age who use hormonal contraceptives (oral or injectable).

• Pregnant or breastfeeding.

• Known sensitivity to any of the components of the formulation

• Gynoid fat distribution.

Related Conditions & MeSH terms

• Obesity
• Overweight
• Overweight and Obesity

Intervention

Dietary Supplement:
• Obex
After concluded the six months of treatment, patients will be follow-up during six months without consumption of Obex
• Placebo
After concluded the six months of treatment, patients will be follow-up during six months without consumption of the placebo.

Locations

Country	Name	City	State
Cuba	National Institute of Endocrinology	Havana	La Habana

Sponsors (1)

Lead Sponsor	Collaborator
Catalysis SL

Country where clinical trial is conducted

Cuba, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Body Weight.	Change in body weight from baseline (0) after six months of treatment (i.e., weight at six month minus weight at baseline 0). Body weight measured in kilograms (k).	Six months
Primary	Change From Baseline in Waist Circumference at Week 24.	Change in waist circumference from baseline after six months of treatment (i.e., waist circumference at six month minus waist circumference at baseline 0). Waist measured in centimeters (cm).	Six months
Primary	To evaluate the effect of Obex® on fasting glucose levels.	The primary outcome is to evaluate the effect of the treatment with Obex® on fasting glucose levels by blood analysis.	Six months
Secondary	To evaluate the effect of Obex® on Body Mass Index (BMI).	The BMI will be measured by Quételet index.	Six months
Secondary	To evaluate the effect of Obex® on the waist and hip ratio.	Waist and hip ratio will be measured according to the World Health Organisation's data gathering protocol.	Six months
Secondary	To evaluate the effect of Obex® on the waist and height ratio.	Waist and height ratio will be measured.	Six months
Secondary	To evaluate the effect of Obex® on arterial blood pressures (BP).	The arterial BP will be evaluated by the doctor.	Six months
Secondary	To evaluate the effect of Obex® on fasting insulin levels.	The insulin levels will be evaluated by blood analysis.	Six months
Secondary	To evaluate the effect of Obex® on insulin resistance.	Homeostasis model assessment-estimated insulin resistance (HOMA-IR), calculated from individual serum measures (fasting insulin x fasting glucose/22.5).	Six months
Secondary	To evaluate the effect of Obex® on insulin sensitivity.	The Quicki, Bennett and Raynaud insulin sensitivity indexes will be evaluated by QUICKI = [1/[log I0 + log G0], Bennett index (BEN) = 1/(log I0 x log G0), Raynaud index (RAY) = [40/I0]).	Six months
Secondary	To evaluate the effect of Obex® on ß-cell function.	Homeostatic model assessment-beta cell (HOMA-ß), calculated from individual serum measures (20 x fasting insulin (µU/mL)/fasting glucose (mmol/L)-3.5).	Six months
Secondary	To evaluate the effect of Obex® on cholesterol.	The cholesterol, triglyceride, HDL-c and LDL-c levels will be evaluated by blood analysis.	Six months
Secondary	To evaluate the effect of Obex® on hepatic enzymes.	The hepatic enzymes (Alanine aminotransferase, Aspartate aminotransferase, gamma-glutamyltransferase, Alkaline Phosphatase) will be evaluated by blood analysis.	Six months
Secondary	To evaluate the effect of Obex® on creatinine and uric acid concentrations.	The creatinine and uric acid levels will be evaluated by blood analysis.	Six months
Secondary	To evaluate the effect of Obex® on haemoglobin levels.	The haemoglobin levels will be evaluated by blood analysis.	Six months
Secondary	To evaluate the effect of Obex® on Conicity Index (CI)	CI will be measured by index.	Six months